Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysisNovo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.{}

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.https://www.cnbc.com/2026/10/20/novo-cagrisema-women-weight-loss-analysis.html